Summary of Incyte Q1 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue:: $1.27 billion, up 21% year-over-year.

Net Sales:: $1.1 billion, representing a 20% increase from the previous year.

Jakafi Sales:: $758 million, a 7% year-over-year growth.

Core Business (excluding Jakafi):: Sales increased by 63% year-over-year, totaling $342 million.

GAAP R&D Expenses:: $516 million, an 18% increase year-over-year.

GAAP SG&A Expenses:: $328 million, a modest 1% increase year-over-year.

Operating Margin Improvement:: Operating expenses grew at a slower rate than revenues, indicating improved operational leverage.

2Strategic Updates and Business Highlights

Incyte is transitioning from reliance on Jakafi to a diversified portfolio in hematology, oncology, and immunology.

Key regulatory milestones include the FDA's acceptance of the application for povorcitinib for hidradenitis suppurativa (HS) and positive Phase III results for vitiligo.

Upcoming product launches include Jakafi XR, Opzelura for atopic dermatitis in Europe, Monjuvi for first-line DLBCL, and povorcitinib for HS.

Significant executive appointments were made to strengthen management, including Suky Upadhyay as CFO and Pablo Cagnoni as President and Global Head of R&D.

3Forward Guidance and Outlook

Full-year 2026 net sales guidance is set between $4.77 billion and $4.94 billion, reflecting a 10% to 13% increase from 2025.

Jakafi sales are expected to be between $3.22 billion and $3.27 billion, while Opzelura is projected to generate $750 million to $790 million.

The core business (excluding Jakafi) is anticipated to approach $3 billion to $4 billion by 2030.

4Bad News, Challenges, or Points of Concern

The company faces competitive pressures in the dermatological market, particularly with Opzelura, as it competes against other non-steroidal topicals.

The reliance on Jakafi, despite its growth, poses a risk as Incyte aims to diversify its portfolio.

The timeline for regulatory approvals, particularly for pivotal studies, could be impacted by ongoing discussions with the FDA regarding endpoints and trial designs.

There is uncertainty regarding the uptake of povorcitinib in the HS market, particularly in distinguishing its use among biologic-naive patients versus those who have failed biologics.

5Notable Q&A Insights

Management expressed optimism about the potential for povorcitinib to capture a significant share of the HS market, targeting both pre- and post-biologic patients.

The company is confident in the unique positioning of its products, with a focus on a "topical to oral" treatment strategy for vitiligo and HS.

Discussions with the FDA have been constructive, particularly regarding the development of the mutant CALR antibody 989, which is expected to initiate Phase III trials mid-year.

Management emphasized the importance of maintaining operational efficiency and strategic capital allocation under the new CFO's leadership.

There was a strong focus on the potential synergies between Jakafi and the new therapies in the pipeline, particularly for patients with CALR mutations in myelofibrosis. Overall, Incyte reported a strong start to 2026 with significant revenue growth and strategic advancements, while also navigating competitive pressures and regulatory challenges.